Doug Chapnick, BioLoomics CEO

Ex­clu­sive: Backed by for­mer Google CEO’s VC, a Col­orado biotech hatch­es plat­form to evolve de­graders

It was 2012, and Doug Chap­nick was fed up with tra­di­tion­al bio­chem­istry re­search.

That kind of think­ing first led him to a De­part­ment of De­fense-fund­ed project, which in­volved white pow­ders and Rube Gold­berg-es­que ex­per­i­ments, and then to found­ing a biotech com­pa­ny called Bi­oLoomics, which is try­ing to de­vel­op new pro­tein de­graders via di­rect­ed evo­lu­tion, or lab-based nat­ur­al se­lec­tion, in hu­man cell ex­per­i­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.